TAK-954: Clinical Trials

6 completed, 1 terminated. 4 Phase 1, 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 4
Phase 2	3	Completed 2, Terminated 1

Follow TAK-954: new trials by email Literature Review of TAK-954 trials Research Report on TAK-954

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants TAK-954, TAK-954 Placebo - Healthy Volunteers	Phase 1	Completed	Millennium Pharmaceuticals, Inc.	6	2019-03-08	2020-06-24
A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery TAK-954 Placebo, TAK-954 - Postoperative Gastrointestinal Dysfunction	Phase 2	Completed	Takeda	209	2019-03-07	2023-06-23
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) TAK-954, Metoclopramide, Normal Saline - Critical Illness, Enteral Nutrition	Phase 2	Terminated	Millennium Pharmaceuticals, Inc.	1	2018-08-25	2019-09-24
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants TAK-954, Placebo - Diabetic Gastroparesis, Idiopathic Gastroparesis	Phase 2	Completed	Takeda	36	2018-01-02	2021-01-07
A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954 TAK-954 - Renal Impairment, Healthy Volunteers	Phase 1	Completed	Takeda	32	2017-11-21	2020-08-25
A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954 TAK-954 - Hepatic Impairment, Healthy Volunteers	Phase 1	Completed	Takeda	25	2017-11-09	2019-09-25
A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants TAK-954, Itraconazole - Healthy Participants	Phase 1	Completed	Takeda	10	2017-05-31	2019-01-15

Conditions studied

Critical Illness (1)  ·  Renal Insufficiency (1)

Sponsors

Takeda (5)  ·  Millennium Pharmaceuticals, Inc. (2)

Countries

United States (5)  ·  Czechia (2)  ·  Australia (1)  ·  Canada (1)  ·  Germany (1)  ·  Hungary (1)  ·  Slovakia (1)  ·  United Kingdom (1)

Results publications

PMID 33711180, PMID 34989180

NIH funding

2017 (4), 2018 (1)